AVXL beat EPS expectations by 19.26%
Feb 12, 2025, 11:32 PM
0.00%
What does AVXL do
Anavex Life Sciences, a New York-based biopharmaceutical company, develops therapeutics for neurodegenerative diseases and employs 40 staff. Its lead compound, ANAVEX 2-73, targets Alzheimer's and Parkinson's diseases.
Anavex Life Sciences (AVXL) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Anavex Life Sciences's actual EPS was -$0.14, beating the estimate of -$0.17 per share, resulting in a 19.26% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.